Inpixon Reports Second Quarter 2023 Financial Results and Provides Business Update
- None.
- None.
Entered into a Definitive Merger Agreement with XTI Aircraft;
Merger Expected to be Completed during the Fourth Quarter of 2023
Business Update Presentation with XTI Aircraft Management
to be Held Today at 4:30 p.m. ET
"During the second quarter we continued our work to explore, identify, and pursue strategic alternatives with the goal of delivering additional value for our shareholders," commented Nadir Ali, CEO of Inpixon. "Towards this end, we're excited to have recently announced entering into a definitive merger agreement with XTI Aircraft, an innovative aviation company developing a vertical lift crossover airplane (VLCA). We believe this transaction will be transformational for Inpixon and XTI, resulting in a public company that will be engaged in both advancing the TriFan 600, a fixed wing, vertical takeoff and landing (VTOL) aircraft, and in offering RTLS solutions to industrial markets. With over 700 conditional pre-orders[1], representing the potential for gross revenues of approximately
"Inpixon improved its gross margins during the quarter as a result of lower cost of goods within the IIoT and SAVES business lines. With RTLS enabling customers to digitally track the location of assets, our customers can locate, learn, and leverage information to make data-driven business decisions. In addition, we have preserved a solid balance sheet with over
[1] Conditional pre-orders refers to a combination of aircraft purchase agreements, non-binding reservation deposit agreements, and options.
[2] Based on XTI's current list price of
Financial Results
Revenues for the three and six months ended June 30, 2023 were
Operating expenses for the three months ended June 30, 2023 were
Net loss from continuing operations for the three months ended June 30, 2023 was
Proforma non-GAAP net loss per basic and diluted common share for the three and six months ended June 30, 2023 was a loss of
Conference Call and Presentation Information
Inpixon will host a conference call presentation today at 4:30 p.m. ET to provide a business update as well as a presentation by the management of XTI Aircraft Company ("XTI") following the recently announced definitive merger agreement between Inpixon and XTI.
Interested parties may access the conference call presentation at https://www.webcaster4.com/Webcast/Page/2235/48894 or at the link on Inpixon's Investor Relations section of the website, ir.inpixon.com/ir-news-events/ir-calendar. A webcast replay will be available on Inpixon's Investor Relations section of the website (ir.inpixon.com/ir-news-events/ir-calendar).
Shareholders and other interested parties are invited to submit questions to Inpixon management via email to inpx@crescendo-ir.com.
About Inpixon
Inpixon® (Nasdaq: INPX) is the innovator of Indoor Intelligence®, delivering actionable insights for people, places and things. Combining the power of mapping, positioning and analytics, Inpixon helps to create smarter, safer, and more secure environments. The company's Indoor Intelligence and industrial real-time location system (RTLS) solutions are leveraged by a multitude of industries to optimize operations, increase productivity, and enhance safety. Inpixon customers can take advantage of industry leading location awareness, analytics, sensor fusion, IIoT and the IoT to create exceptional experiences and to do good with indoor data. For the latest insights, follow Inpixon on LinkedIn, and Twitter, and visit inpixon.com.
About XTI
XTI Aircraft Company is an aviation business based near
Non-GAAP Financial Measures
Management believes that certain financial measures not in accordance with generally accepted accounting principles in
Management provides Adjusted EBITDA and pro forma net loss per share measures so that investors will have the same financial information that management uses, which may assist investors in assessing Inpixon's performance on a period-over-period basis. Adjusted EBITDA or pro forma net loss per share is not a measure of financial performance under GAAP and should not be considered an alternative to net income (loss) or any other measure of performance under GAAP, or to cash flows from operating, investing or financing activities as an indicator of cash flows or as a measure of liquidity. Adjusted EBITDA and pro forma net loss per share have limitations as analytical tools and should not be considered either in isolation or as a substitute for analysis of Inpixon's results as reported under GAAP.
For more information on our non-GAAP financial measures and a reconciliation of GAAP to non-GAAP measures, please see the "Reconciliation of Non-GAAP Financial Measures" table accompanying this press release.
Contacts
Inpixon Contacts
General inquiries:
Email: marketing@inpixon.com
Web: inpixon.com/contact-us
Investor relations:
Crescendo Communications for Inpixon
Tel: +1 212-671-1020
Email: INPX@crescendo-ir.com
XTI Aircraft Contacts
General inquiries:
Email: liftup@xtiaircraft.com
Web: xtiaircraft.com/cm/get-involved
Investor relations:
Crescendo Communications for XTI
Tel: +1 212-671-1020
Email: XTI@crescendo-ir.com
Important Information About the Proposed Transaction and Where to Find It
This press release relates to a proposed transaction between XTI Aircraft Company, a
Before making any voting decision, investors and security holders are urged to read the registration statement, the proxy statement/prospectus, and amendments thereto, and the definitive proxy statement/prospectus in connection with Inpixon's solicitation of proxies for its stockholders' meeting to be held to approve the transaction, and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about Inpixon, XTI and the proposed transaction.
Investors and securityholders will be able to obtain free copies of the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by Inpixon through the website maintained by the SEC at www.sec.gov.
The documents filed by Inpixon with the SEC also may be obtained free of charge at Inpixon's website at www.inpixon.com or upon written request to: Inpixon, 2479 E. Bayshore Road, Suite 195,
NEITHER THE SEC NOR ANY STATE SECURITIES REGULATORY AGENCY HAS APPROVED OR DISAPPROVED THE TRANSACTIONS DESCRIBED IN THIS COMMUNICATION, PASSED UPON THE MERITS OR FAIRNESS OF THE TRANSACTION OR RELATED TRANSACTIONS OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THIS COMMUNICATION. ANY REPRESENTATION TO THE CONTRARY CONSTITUTES A CRIMINAL OFFENSE.
Forward-Looking Statements
This communication contains certain "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this communication, including statements regarding the benefits of the proposed transaction, the anticipated timing of the completion of the proposed transaction, the products under development by XTI and the markets in which it plans to operate, the advantages of XTI's technology, XTI's competitive landscape and positioning, and XTI's growth plans and strategies, are forward-looking statements.
Some of these forward-looking statements can be identified by the use of forward-looking words, including "may," "should," "expect," "intend," "will," "estimate," "anticipate," "believe," "predict," "plan," "targets," "projects," "could," "would," "continue," "forecast" or the negatives of these terms or variations of them or similar expressions. All forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. All forward-looking statements are based upon estimates, forecasts and assumptions that, while considered reasonable by Inpixon and its management, and XTI and its management, as the case may be, are inherently uncertain and many factors may cause the actual results to differ materially from current expectations which include, but are not limited to:
- the risk that the proposed transaction may not be completed in a timely manner or at all, which may adversely affect the price of Inpixon's securities;
- the failure to satisfy the conditions to the consummation of the proposed transaction, including the adoption of the merger agreement by the shareholders of Inpixon;
- the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement;
- the adjustments permitted under the merger agreement to the exchange ratio that could result in XTI shareholders or Inpixon shareholders owning less of the post-combination company than expected;
- the effect of the announcement or pendency of the proposed transaction on Inpixon's and XTI's business relationships, performance, and business generally;
- risks that the proposed transaction disrupts current plans of Inpixon and XTI and potential difficulties in Inpixon's and XTI's employee retention as a result of the proposed transaction;
- the outcome of any legal proceedings that may be instituted against XTI or against Inpixon related to the merger agreement or the proposed transaction;
- failure to realize the anticipated benefits of the proposed transaction;
- the inability to meet and maintain the listing of Inpixon's securities (or the securities of the post-combination company) on Nasdaq;
- the risk that the price of Inpixon's securities (or the securities of the postcombination company) may be volatile due to a variety of factors, including changes in the highly competitive industries in which Inpixon and XTI operate,
- the inability to implement business plans, forecasts, and other expectations after the completion of the proposed transaction, and identify and realize additional opportunities;
- variations in performance across competitors, changes in laws, regulations, technologies that may impose additional costs and compliance burdens on Inpixon and XTI's operations, global supply chain disruptions and shortages,
- national security tensions, and macro-economic and social environments affecting Inpixon and XTI's business and changes in the combined capital structure;
- the risk that XTI has a limited operating history, has not yet manufactured any non-prototype aircraft or delivered any aircraft to a customer, and XTI and its current and future collaborators may be unable to successfully develop and market XTI's aircraft or solutions, or may experience significant delays in doing so;
- the risk that XTI is subject to the uncertainties associated with the regulatory approvals of its aircraft including the certification by the Federal Aviation Administration, which is a lengthy and costly process;
- the risk that the post-combination company may never achieve or sustain profitability;
- the risk that XTI, Inpixon and the post-combination company may be unable to raise additional capital on acceptable terms to finance its operations and remain a going concern;
- the risk that the post-combination company experiences difficulties in managing its growth and expanding operations;
- the risk that XTI's conditional pre orders (which include conditional aircraft purchase agreements, non-binding reservations, and options) are canceled, modified, delayed or not placed and that XTI must return the refundable deposits;
- the risks relating to long development and sales cycles, XTI's ability to satisfy the conditions and deliver on the orders and reservations, its ability to maintain quality control of its aircraft, and XTI's dependence on third parties for supplying components and potentially manufacturing the aircraft;
- the risk that other aircraft manufacturers develop competitive VTOL aircraft or other competitive aircraft that adversely affect XTI's market position;
- the risk that XTI's future patent applications may not be approved or may take longer than expected, and XTI may incur substantial costs in enforcing and protecting its intellectual property;
- the risk that XTI's estimates of market demand may be inaccurate;
- the risk that XTI's ability to sell its aircraft may be limited by circumstances beyond its control, such as a shortage of pilots and mechanics who meet the training standards, high maintenance frequencies and costs for the sold aircraft, and any accidents or incidents involving VTOL aircraft that may harm customer confidence;
- other risks and uncertainties set forth in the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in Inpixon's Annual Report on Form 10-K for the year ended December, 31, 2022, which was filed with the SEC on April 17, 2023 (the "2022 Form 10-K") and Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 filed on May 16, 2023, and in the section entitled "Risk Factors" in XTI's periodic reports filed pursuant to Regulation A of the Securities Act including XTI's Annual Report on Form 1-K for the year ended December 31, 2022, which was filed with the SEC on July 13, 2023 (the "2022 Form 1-K"), as such factors may be updated from time to time in Inpixon's and XTI's filings with the SEC, the registration statement on Form S-4 and the proxy statement/prospectus contained therein. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Neither Inpixon nor XTI gives any assurance that either Inpixon or XTI or the post-combination company will achieve its expected results. Neither Inpixon nor XTI undertakes any duty to update these forward-looking statements, except as otherwise required by law.
Participants in the Solicitation
XTI and Inpixon and their respective directors and officers and other members of management may, under SEC rules, be deemed to be participants in the solicitation of proxies from Inpixon's stockholders with the proposed transaction and the other matters set forth in the registration statement. Information about Inpixon's and XTI's directors and executive officers is set forth in Inpixon's filings and XTI's filings with the SEC, including Inpixon's 2022 Form 10-K and XTI's 2022 Form 1-K. Additional information regarding the direct and indirect interests, by security holdings or otherwise, of those persons and other persons who may be deemed participants in the proposed transaction may be obtained by reading the proxy statement/prospectus regarding the proposed transaction when it becomes available. You may obtain free copies of these documents as described above under "Important Information About the Proposed Transaction and Where to Find It."
No Offer or Solicitation
This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction and is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy, sell or solicit any securities or any proxy, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be deemed to be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.
INPIXON AND SUBSIDIARIES | |||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
(In thousands, except number of shares and par value data) | |||||||
As of | |||||||
June 30, | December 31, | ||||||
(Unaudited) | (Audited) | ||||||
ASSETS | |||||||
Current Assets | |||||||
Cash and cash equivalents | $ | 15,681 | $ | 10,235 | |||
Accounts receivable, net of allowances of | 1,803 | 1,889 | |||||
Notes and other receivables | 785 | 86 | |||||
Inventory | 3,228 | 2,442 | |||||
Note receivable | -- | 150 | |||||
Prepaid assets and other current assets | 2,181 | 2,803 | |||||
Current assets of discontinued operations | -- | 12,261 | |||||
Total Current Assets | 23,678 | 29,866 | |||||
Property and equipment, net | 1,009 | 1,064 | |||||
Operating lease right-of-use asset, net | 434 | 531 | |||||
Software development costs, net | 1,113 | 1,265 | |||||
Investment in equity securities | 1,414 | 330 | |||||
Long-term investments | 50 | 716 | |||||
Intangible assets, net | 2,573 | 2,994 | |||||
Other assets | 174 | 158 | |||||
Non-current assets of discontinued operations | -- | 20,711 | |||||
Total Assets | $ | 30,445 | $ | 57,635 | |||
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
Current Liabilities | |||||||
Accounts payable | $ | 1,665 | $ | 1,503 | |||
Accrued liabilities | 5,374 | 2,619 | |||||
Operating lease obligation, current | 200 | 211 | |||||
Deferred revenue | 1,124 | 1,323 | |||||
Short-term debt | 13,800 | 13,643 | |||||
Acquisition liability | -- | 197 | |||||
Warrant Liability | 1,500 | -- | |||||
Current liabilities of discontinued operations | -- | 5,218 | |||||
Total Current Liabilities | 23,663 | 24,714 | |||||
Long Term Liabilities | |||||||
Operating lease obligations, noncurrent | 245 | 334 | |||||
Non-current liabilities of discontinued operations | -- | 472 | |||||
Total Liabilities | 23,908 | 25,520 | |||||
Commitments and Contingencies | -- | -- | |||||
Stockholders' Equity | |||||||
Preferred Stock - | |||||||
Series 4 Convertible Preferred Stock - 10,415 shares authorized; 1 issued and 1 outstanding as of June 30, 2023 and December 31, 2022, respectively; | -- | -- | |||||
Series 5 Convertible Preferred Stock - 12,000 shares authorized; 126 issued and 126 outstanding as of June 30, 2023 and December 31, 2022, respectively. | -- | -- | |||||
Common Stock - | 43 | 4 | |||||
Additional paid-in capital | 346,799 | 346,668 | |||||
Treasury stock, at cost, 1 share | (695) | (695) | |||||
Accumulated other comprehensive (loss) income | (189) | 1,061 | |||||
Accumulated deficit | (337,555) | (313,739) | |||||
Stockholders' Equity Attributable to Inpixon | 8,403 | 33,299 | |||||
Non-controlling interest | (1,866) | (1,184) | |||||
Total Stockholders' Equity | 6,537 | 32,115 | |||||
Total Liabilities and Stockholders' Equity | $ | 30,445 | $ | 57,635 |
INPIXON AND SUBSIDIARIES | |||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | |||||||||||||
(In thousands, except share and per share data) | |||||||||||||
For the Three Months Ended | For the Six Months Ended | ||||||||||||
June 30, | June 30, | ||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||
(Unaudited) | |||||||||||||
Revenues | $ | 2,057 | $ | 2,576 | $ | 5,161 | $ | 5,225 | |||||
Cost of Revenues | 390 | 856 | 1,180 | 1,653 | |||||||||
Gross Profit | 1,667 | 1,720 | 3,981 | 3,572 | |||||||||
Operating Expenses | |||||||||||||
Research and development | 2,051 | 2,482 | 4,033 | 4,576 | |||||||||
Sales and marketing | 1,241 | 754 | 2,357 | 1,924 | |||||||||
General and administrative | 4,236 | 5,294 | 9,850 | 12,658 | |||||||||
Acquisition related costs | 523 | 137 | 687 | 252 | |||||||||
Transaction costs | 43 | -- | 1,443 | -- | |||||||||
Impairment of goodwill | -- | 2,030 | -- | 2,030 | |||||||||
Amortization of intangibles | 230 | 396 | 450 | 743 | |||||||||
Total Operating Expenses | 8,324 | 11,093 | 18,820 | 22,183 | |||||||||
Loss from Operations | (6,657) | (9,373) | (14,839) | (18,611) | |||||||||
Other (Expense) Income | |||||||||||||
Interest (expense)/ income, net | (1,756) | 168 | (3,481) | 169 | |||||||||
Other income/(expense), net | 1,183 | 15 | 1,212 | (28) | |||||||||
Unrealized gain/(loss) on equity securities | (92) | 247 | (58) | (1,256) | |||||||||
Total Other Expense | (665) | 430 | (2,327) | (1,115) | |||||||||
Net Loss from Continuing Operations, before tax | (7,322) | (8,943) | (17,166) | (19,726) | |||||||||
Income tax provision | (7) | (22) | (2,485) | (22) | |||||||||
Net Loss from Continuing Operations | (7,329) | (8,965) | (19,651) | (19,748) | |||||||||
Loss from Discontinued Operations, Net of Tax | -- | (11,365) | (4,856) | (12,139) | |||||||||
Net Loss | (7,329) | (20,330) | (24,507) | (31,887) | |||||||||
Net Loss Attributable to Non-controlling Interest | (363) | (458) | (667) | (804) | |||||||||
Net Loss Attributable to Stockholders of Inpixon | $ | (6,966) | $ | (19,872) | $ | (23,840) | $ | (31,083) | |||||
Accretion of Series 7 preferred stock | -- | -- | -- | (4,555) | |||||||||
Accretion of Series 8 Preferred Stock | -- | (6,237) | -- | (6,785) | |||||||||
Deemed dividend for the modification related to Series 8 Preferred Stock | -- | -- | -- | (2,627) | |||||||||
Deemed contribution for the modification related to Warrants issued in connection with Series 8 Preferred Stock | -- | -- | -- | 1,469 | |||||||||
Amortization premium- modification related to Series 8 Preferred Stock | -- | 1,252 | -- | 1,362 | |||||||||
Net Loss Attributable to Common Stockholders | $ | (6,966) | $ | (24,857) | $ | (23,840) | $ | (42,219) | |||||
Net Loss Per Share - Basic and Diluted | |||||||||||||
Continuing Operations | $ | (0.19) | $ | (6.99) | $ | (0.92) | $ | (14.90) | |||||
Discontinued Operations | $ | -- | $ | (5.88) | $ | (0.24) | $ | (6.01) | |||||
Net Loss Per Share - Basic and Diluted | $ | (0.19) | $ | (12.87) | $ | (1.16) | $ | (20.91) | |||||
Weighted Average Shares Outstanding | |||||||||||||
Basic and Diluted | 37,442,387 | 1,931,535 | 20,600,208 | 2,018,295 | |||||||||
Comprehensive Loss | |||||||||||||
Net Loss | $ | (7,329) | $ | (20,330) | $ | (24,507) | $ | (31,887) | |||||
Unrealized gain on available for sale debt securities | -- | 375 | -- | 375 | |||||||||
Unrealized foreign exchange loss from cumulative translation adjustments | 9 | 281 | (1,250) | 180 | |||||||||
Comprehensive Loss | $ | (7,320) | $ | (19,674) | $ | (25,757) | $ | (31,332) |
INPIXON AND SUBSIDIARIES | ||||||
CONSOLIDATED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||
(In thousands) | ||||||
For the Six Months Ended | ||||||
June 30, | ||||||
2023 | 2022 | |||||
(Unaudited) | ||||||
Cash Flows Used In Operating Activities | ||||||
Net loss | $ | (24,507) | $ | (31,887) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Depreciation and amortization | 624 | 650 | ||||
Amortization of intangible assets | 1,255 | 3,026 | ||||
Amortization of right of use asset | 158 | 353 | ||||
Stock based compensation | 570 | 2,274 | ||||
Amortization of warrant liability to redemption value | 20 | -- | ||||
Earnout expense valuation benefit | -- | (2,827) | ||||
Gain on settlement with FOXO | (1,142) | -- | ||||
Amortization of debt issuance costs | 1,686 | (92) | ||||
Unrealized gain on note | -- | 344 | ||||
Unrealized loss on foreign currency transactions | (178) | -- | ||||
Distribution of equity method investment shares to employees as compensation | 666 | -- | ||||
Deferred income tax | 2,591 | (1) | ||||
Unrealized loss on equity securities | 58 | 1,256 | ||||
Impairment of goodwill | -- | 7,570 | ||||
Gain on fair value of warrant liability | 71 | -- | ||||
Other | 22 | 181 | ||||
Changes in operating assets and liabilities: | ||||||
Accounts receivable and other receivables | (1,016) | 361 | ||||
Inventory | (779) | 285 | ||||
Prepaid expenses and other current assets | 890 | 1,357 | ||||
Other assets | (4) | 25 | ||||
Accounts payable | (634) | (1,498) | ||||
Accrued liabilities | 3,796 | 542 | ||||
Income tax liabilities | (119) | (40) | ||||
Deferred revenue | 325 | (1,096) | ||||
Operating lease obligation | (158) | (327) | ||||
Net Cash Used in Operating Activities | $ | (15,805) | $ | (19,544) | ||
Cash Flows Used in Investing Activities | ||||||
Purchase of property and equipment | (45) | (140) | ||||
Investment in capitalized software | (135) | (306) | ||||
Purchase of convertible note | -- | (5,500) | ||||
Sales of treasury bills | -- | 43,001 | ||||
Proceeds from repayment of note receivable | 150 | -- | ||||
Issuance of note receivable | (450) | -- | ||||
Net Cash (Used in) Provided By Investing Activities | $ | (480) | $ | 37,055 | ||
Cash From Financing Activities | ||||||
Net proceeds from issuance of preferred stock and warrants | $ | -- | 46,906 | |||
Net proceeds from promissory note | 125 | 364 | ||||
Net proceeds from ATM | 20,383 | -- | ||||
Cash paid for redemption of preferred stock series 7 | -- | (49,250) | ||||
Taxes paid related to net share settlement of restricted stock units | -- | (336) | ||||
Net proceeds from issuance of warrants | 1,409 | -- | ||||
Repayment of CXApp acquisition liability | (197) | (1,847) | ||||
Common shares issued for net proceeds from warrants | 1 | -- | ||||
Distribution to shareholders related to spin-off of CXApp | (10,003) | -- | ||||
Net Cash Provided By (Used in) Financing Activities | $ | 11,718 | $ | (4,163) | ||
Effect of Foreign Exchange Rate on Changes on Cash | 13 | (73) | ||||
Net (Decrease) Increase in Cash and Cash Equivalents | (4,554) | 13,275 | ||||
Cash and Cash Equivalents - Beginning of year | 20,235 | 52,480 | ||||
Cash and Cash Equivalents - End of year | $ | 15,681 | $ | 65,755 |
Reconciliation of Non-GAAP Financial Measures: | ||||||||
For the 3 Months Ended | For the 6 Months Ended | |||||||
(In thousands) | June 30, | June 30, | ||||||
2023 | 2022 | 2023 | 2022 | |||||
Net loss attributable to common stockholders | $ (6,966) | $ (24,857) | $ (23,840) | $ (42,219) | ||||
Loss from discontinued operations, net of tax | - | 11,365 | 4,856 | 12,139 | ||||
Interest expense/(income), net | 1,756 | (168) | 3,481 | (169) | ||||
Income tax provision | 7 | 22 | 2,485 | 22 | ||||
Depreciation and amortization | 425 | 737 | 844 | 1,418 | ||||
EBITDA | (4,778) | (12,901) | (12,174) | (28,809) | ||||
Adjusted for: | ||||||||
Non-recurring one-time charges: | ||||||||
Unrealized (gain)/loss on equity securities | 92 | (247) | 58 | 1,256 | ||||
Acquisition transaction/financing costs | 523 | 137 | 687 | 252 | ||||
Professional service fees | - | - | - | 8 | ||||
Impairment of goodwill | - | 2,030 | - | 2,030 | ||||
Transaction costs | 43 | - | 1,443 | - | ||||
Accretion of series 7 preferred stock | - | - | - | 4,555 | ||||
Accretion of series 8 preferred stock | - | 6,237 | - | 6,785 | ||||
Deemed dividend for the modification related to Series 8 preferred stock | - | - | - | 2,627 | ||||
Deemed contribution for the modification related to warrants issued in connection with the Series 8 Preferred Stock | - | - | - | (1,469) | ||||
Amortization premium - modification to Series 8 preferred stock | - | (1,252) | - | (1,362) | ||||
Distribution of equity method investment shares to employees as compensation | - | - | 666 | - | ||||
Gain on equity securities | (1,142) | - | (1,142) | - | ||||
Unrealized foreign exchange (gains)/losses | 28 | 35 | (145) | 124 | ||||
Bad debts expense/provision | 24 | - | 24 | - | ||||
Reserve for inventory obsolescence | 16 | - | 16 | - | ||||
Stock-based compensation – compensation and related benefits | 241 | 741 | 570 | 2,274 | ||||
Severance costs | - | - | 127 | 62 | ||||
Adjusted EBITDA | $ (4,953) | $ (5,220) | $ (9,870) | $ (11,667) | ||||
For the 3 Months Ended | For the 6 Months Ended | |||||||
(In thousands, except share data) | June 30, | June 30, | ||||||
2023 | 2022 | 2023 | 2022 | |||||
Net loss attributable to common stockholders | $ (6,966) | $ (24,857) | $ (23,840) | $ (42,219) | ||||
Adjustments: | ||||||||
Non-recurring one-time charges: | ||||||||
Loss from discontinued operations, net of tax | - | 11,365 | 4,856 | 12,139 | ||||
Unrealized (gain)/loss on equity securities | 92 | (247) | 58 | 1,256 | ||||
Acquisition transaction/financing costs | 523 | 137 | 687 | 252 | ||||
Professional service fees | - | - | - | 8 | ||||
Impairment of goodwill | - | 2,030 | - | 2,030 | ||||
Transaction costs | 43 | - | 1,443 | - | ||||
Accretion of series 7 preferred stock | - | - | - | 4,555 | ||||
Accretion of series 8 preferred stock | - | 6,237 | - | 6,785 | ||||
Deemed dividend for the modification Series 8 preferred stock | - | - | - | 2,627 | ||||
Deemed contribution for the modification related to warrants issued in connection with the Series 8 Preferred Stock | - | - | - | (1,469) | ||||
Amortization premium - modification to Series 8 preferred stock | - | (1,252) | - | (1,362) | ||||
Distribution of equity method investment shares to employees as compensation | - | - | 666 | - | ||||
Gain on equity securities | (1,142) | - | (1,142) | - | ||||
Unrealized foreign exchange (gains)/losses | 28 | 35 | (145) | 124 | ||||
Bad debts expense/provision | 24 | - | 24 | - | ||||
Reserve for inventory obsolescence | 16 | - | 16 | - | ||||
Stock-based compensation - compensation and related benefits | 241 | 741 | 570 | 2,274 | ||||
Severance costs | - | - | 127 | 62 | ||||
Amortization of intangibles | 230 | 563 | 449 | 1,078 | ||||
Proforma non-GAAP net loss | $ (6,911) | $ (5,248) | $ (16,231) | $ (11,860) | ||||
Proforma non-GAAP net loss per basic and diluted common share | $ (0.18) | $ (2.72) | $ (0.79) | $ (5.88) | ||||
Weighted average basic and diluted common shares outstanding | 37,442,387 | 1,931,535 | 20,600,208 | 2,018,295 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/inpixon-reports-second-quarter-2023-financial-results-and-provides-business-update-301899837.html
SOURCE Inpixon
FAQ
What is Inpixon's merger agreement with XTI Aircraft about?
When is the merger with XTI Aircraft expected to be completed?
How many conditional pre-orders does Inpixon have for the TriFan 600?